Kimberley Iris Hemelrijk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kimberley Iris Hemelrijk has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Ronak Delewi
Department of Cardiology, Amsterdam University Medical Centres, Amsterdam, the Netherlands
5 shared publications Didier Tchétché
3 shared publicationsFabio S. de Brito
3 shared publications- Matteo Pagnesi
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
3 shared publications Nicolas Dumonteil
3 shared publications- Ran Kornowski
Rabin Medical Centre
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in Structural Heart
Permanent Pacemaker Implantation in Patients Undergoing Transcatheter Aortic Valve Implantation: From Incidence to Outcomes
- 3 November 2026
- Published by Elsevier in Structural Heart
Open AccessPermanent Pacemaker Implantation in Patients Undergoing Transcatheter Aortic Valve Implantation: From Incidence to Outcomes
- Open Access
- 24 May 2026
- Published by Elsevier in Atherosclerosis
- Vol. 417, 120731
The global burden of calcified aortic valve stenosis: epidemiology, risk factors, disparities, and future perspectives – a narrative review
- 24 May 2026
- Published by Elsevier in Atherosclerosis
- Vol. 417, 120731
Open AccessThe global burden of calcified aortic valve stenosis: epidemiology, risk factors, disparities, and future perspectives – a narrative review
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e045763
Surgical Versus Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis: 1‐Year Clinical Outcomes in Patients Aged 65 Years and Older
Background: Transcatheter aortic valve replacement (TAVR) has shown noninferiority to surgical aortic valve replacement (SAVR). However, patients with bicuspid aortic stenosis are often excluded from these studies. More insights between these procedures in this population is crucial for treatment selection. Methods: In this multicenter observational study, patients with bicuspid aortic stenosis undergoing TAVR or SAVR were analyzed using propensity score matching. The primary outcome was a composite of all‐cause mortality, stroke, rehospitalization, or valve dysfunction at 1 year. Results: A total of 997 patients with bicuspid aortic stenosis underwent TAVR or SAVR. In the matched cohort of 256 pairs, the median age was 75.0 years (interquartile range, 71.0–78.0), 234 (44.9%) were women, and the median EuroScore II was 1.83% (interquartile range, 1.34–2.86). One‐year cumulative incidence of the primary outcome was 15.0% in TAVR compared with 12.0% in SAVR (hazard ratio [HR], 1.35 [95% CI, 0.83–2.19], P =0.23). Mortality (4.3% versus 5.0%, P =0.72) and rehospitalization (4.8% versus 6.4%, P =0.45) were similar between groups. Although rates of valve dysfunction (2.9% versus 0.5%, P =0.06) and stroke (5.3% versus 2.3%, P =0.10) were numerically lower in the surgical group at 1 year, both the risk of stroke (subdistribution HR, 3.01, P =0.02) and valve dysfunction (subdistribution HR, 4.16, P =0.03) were significantly higher in the TAVR group at 2 years. Conclusions: TAVR in patients with bicuspid aortic stenosis showed a similar 1‐year primary outcome rate compared with SAVR, though TAVR exhibited higher rates of valve dysfunction and stroke. These findings underscore the need for randomized trials to define the optimal treatment strategy for this population.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e045763
Open AccessSurgical Versus Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis: 1‐Year Clinical Outcomes in Patients Aged 65 Years and Older
Background: Transcatheter aortic valve replacement (TAVR) has shown noninferiority to surgical aortic valve replacement (SAVR). However, patients with bicuspid aortic stenosis are often excluded from these studies. More insights between these procedures in this population is crucial for treatment selection. Methods: In this multicenter observational study, patients with bicuspid aortic stenosis undergoing TAVR or SAVR were analyzed using propensity score matching. The primary outcome was a composite of all‐cause mortality, stroke, rehospitalization, or valve dysfunction at 1 year. Results: A total of 997 patients with bicuspid aortic stenosis underwent TAVR or SAVR. In the matched cohort of 256 pairs, the median age was 75.0 years (interquartile range, 71.0–78.0), 234 (44.9%) were women, and the median EuroScore II was 1.83% (interquartile range, 1.34–2.86). One‐year cumulative incidence of the primary outcome was 15.0% in TAVR compared with 12.0% in SAVR (hazard ratio [HR], 1.35 [95% CI, 0.83–2.19], P =0.23). Mortality (4.3% versus 5.0%, P =0.72) and rehospitalization (4.8% versus 6.4%, P =0.45) were similar between groups. Although rates of valve dysfunction (2.9% versus 0.5%, P =0.06) and stroke (5.3% versus 2.3%, P =0.10) were numerically lower in the surgical group at 1 year, both the risk of stroke (subdistribution HR, 3.01, P =0.02) and valve dysfunction (subdistribution HR, 4.16, P =0.03) were significantly higher in the TAVR group at 2 years. Conclusions: TAVR in patients with bicuspid aortic stenosis showed a similar 1‐year primary outcome rate compared with SAVR, though TAVR exhibited higher rates of valve dysfunction and stroke. These findings underscore the need for randomized trials to define the optimal treatment strategy for this population.
- Open Access
- 21 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (1) , 114-123
Pre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation
Background: Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting. Aims: To assess clinical outcomes in patients with severe aortic valve stenosis with AF who undergo TAVI in a large real‐world global cohort. Methods: The CENTER2‐study includes 25,771 patients that underwent TAVI between 2007 and 2022. The database consists of patient‐level pooled data from 10 clinical studies. Objectives were rates of new‐onset AF ≤ 30 days, and differences in mortality and stroke according to AF status. Results: A total of 23,320 patients were included in the current analysis (56.1% female; mean age 81.5 ± 6.7 years). Pre‐existing AF was present in 28.2% ( n = 6579) of patients. Mortality rates after TAVI were higher in patients with pre‐existing AF (19.0% vs. 14.2%, adjusted HR: 1.39, 95% CI: 1.26–1.53, p < 0.001). Strokes at Day 3–30 after TAVI were more frequent in patients with pre‐existing AF (1.6% vs. 1.1%, p = 0.004). New‐onset AF occurred in 6.2% ( n = 681) of patients without pre‐existing AF. Mortality rates after TAVI were higher in patients with new‐onset AF (adjusted HR 1.75, 95% CI 1.24–2.49, p = 0.002). One‐year stroke was more frequently observed in patients with new‐onset AF after exclusion of acute periprocedural stroke (6.1% vs. 3.4%, p = 0.04). Major bleeding was also more frequent in patients with new‐onset AF (12.0% vs. 6.7%, p < 0.001). Conclusions: Patients with pre‐existing or new‐onset AF had higher mortality compared with patients without AF undergoing transfemoral TAVI. After the acute postprocedural period, 1‐year stroke rates were higher in patients with new‐onset AF. Trial Registration: ClinicalTrials.gov . Unique identifier NCT03588247.
- 21 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (1) , 114-123
Open AccessPre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation
Background: Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting. Aims: To assess clinical outcomes in patients with severe aortic valve stenosis with AF who undergo TAVI in a large real‐world global cohort. Methods: The CENTER2‐study includes 25,771 patients that underwent TAVI between 2007 and 2022. The database consists of patient‐level pooled data from 10 clinical studies. Objectives were rates of new‐onset AF ≤ 30 days, and differences in mortality and stroke according to AF status. Results: A total of 23,320 patients were included in the current analysis (56.1% female; mean age 81.5 ± 6.7 years). Pre‐existing AF was present in 28.2% ( n = 6579) of patients. Mortality rates after TAVI were higher in patients with pre‐existing AF (19.0% vs. 14.2%, adjusted HR: 1.39, 95% CI: 1.26–1.53, p < 0.001). Strokes at Day 3–30 after TAVI were more frequent in patients with pre‐existing AF (1.6% vs. 1.1%, p = 0.004). New‐onset AF occurred in 6.2% ( n = 681) of patients without pre‐existing AF. Mortality rates after TAVI were higher in patients with new‐onset AF (adjusted HR 1.75, 95% CI 1.24–2.49, p = 0.002). One‐year stroke was more frequently observed in patients with new‐onset AF after exclusion of acute periprocedural stroke (6.1% vs. 3.4%, p = 0.04). Major bleeding was also more frequent in patients with new‐onset AF (12.0% vs. 6.7%, p < 0.001). Conclusions: Patients with pre‐existing or new‐onset AF had higher mortality compared with patients without AF undergoing transfemoral TAVI. After the acute postprocedural period, 1‐year stroke rates were higher in patients with new‐onset AF. Trial Registration: ClinicalTrials.gov . Unique identifier NCT03588247.
- Open Access
- 14 February 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 81, 103092
Cerebral blood flow and cognitive functioning in patients undergoing transcatheter aortic valve implantation
- 14 February 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 81, 103092
Open AccessCerebral blood flow and cognitive functioning in patients undergoing transcatheter aortic valve implantation
- Open Access
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e032901
Cerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient‐Level Study
Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real‐world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI. Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon‐Expandable Valves Versus Self‐Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient‐level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%–8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007–2010: 2.1%, 2011–2014: 2.5%, 2015–2018: 2.1%, 2019–2022: 2.1%; P trend =0.28). Moreover, 30‐day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low‐risk, 2.6% in intermediate‐risk, and 2.5% in high‐risk patients ( P =0.21). Mortality was higher in patients with 30‐day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1–6.5]; P P P trend =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke. Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30‐day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty‐day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03588247.
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e032901
Open AccessCerebrovascular Events in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation: A Pooled Patient‐Level Study
Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real‐world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI. Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon‐Expandable Valves Versus Self‐Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient‐level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%–8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007–2010: 2.1%, 2011–2014: 2.5%, 2015–2018: 2.1%, 2019–2022: 2.1%; P trend =0.28). Moreover, 30‐day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low‐risk, 2.6% in intermediate‐risk, and 2.5% in high‐risk patients ( P =0.21). Mortality was higher in patients with 30‐day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1–6.5]; P P P trend =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke. Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30‐day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty‐day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03588247.
- Open Access
- 15 March 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 10, 101746
A Travel Through Time
- 15 March 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 10, 101746
Open AccessA Travel Through Time